Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis Aug 23, 2021 7:01am EDT
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates Aug 12, 2021 4:02pm EDT
Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021 Jul 08, 2021 7:01am EDT
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021 Jun 02, 2021 7:01am EDT
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors Jun 01, 2021 4:01pm EDT
Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference May 27, 2021 7:00am EDT
Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021 May 26, 2021 4:01pm EDT
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates May 12, 2021 4:01pm EDT
